Skip to main content

Table 3 Changes in clinical, endoscopic, and histologic evidence of disease by subject

From: Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study

  Study code Age Sex Extent of disease Duration of disease (yrs) Maintenance therapy BMI Change in total Mayo score Change in endoscopic UCEIS score Change in endoscopic Mayo score Change in histologic score Change in fecal calprotectin (mcg/g) Change in total IBDQ score
FMT E 46 F Pan-colitis 5.5 Mesalamine 20.9  − 7  − 2 0  − 3  − 285 92
W 35 M Pan-colitis 7.5 Vedolizumab 27.8  − 3  − 1 0  − 1.3  − 189 47
F 20 M Pan-colitis 3.8 Mesalamine 25  − 1  − 1 0  − 2  − 164 16
A 65 F L-sided 26.2 Mesalamine 20.9 3 0 1  − 1.2 ? =  > 375 8
N 44 M Pan-colitis 0.2 Sulfasalazine 25.6 1  − 3 0 0.9  > 1000 =  > > 1000 59
P 38 M Pan-colitis 10.2 Mercaptopurine 25.2  − 3 2  − 1 0  − 42 32
Placebo B 68 M Pan-colitis 4.4 Mesalamine 28.8  − 2  − 1 0 0.8  − 132 21
G 58 M L-sided 27.8 Mesalamine 26.9 1 0 0  − 2 4 32
Y 65 M L-sided 0.4 Mesalamine 36.15 0 0 0 0 74 4
V 47 F Pan-colitis 8.8 Adalimumab 29.2  − 1 0 0 0 27 35
T 31 F Pan-colitis 0.8 Mesalamine 29.1 0  − 1 0 0  − 137 32
I 40 F Pan-colitis 16.3 Mesalamine 25 Dropped out due to worsening disease activity
  1. IBDQ, Inflammatory Bowel Disease Questionnaire; L-Sides, left-sided disease; BMI, Body Mass Index; yrs, years; wks, weeks
  2. ^Ulcerative Colitis Endoscopic Index of Severity
  3. *Geboes Score